

Index

A

- Academy of Managed Care Pharmacy, 88
Adverse drug events (ADEs), 32–35, 91, 99, 100
Ambulatory care
 chain drugstores and, 166
 formulary system and, 47–48
 hospital pharmacy's role in, 154
 implications in, 164
 patient counseling in, 126–127
 pharmaceutical prices and, 66–67
 pharmaceutical services and, 9–10, 63
American Association of Colleges of Pharmacy, 49, 88, 111, 132, 162
American College of Clinical Pharmacy, 88, 132
American Hospital Association, 51, 52
American Hospital Formulary Service, 173, 176
American Institute of the History of Pharmacy, 179
American Medical Association, 51, 52, 56, 144
American Nurses' Association, 144
American Pharmaceutical Association, 51, 52, 88, 132, 162–164, 167–168, 174, 175
American Society of Consultant Pharmacists, 88, 132, 167
American Society of Health-System Pharmacists
 challenges faced by, 153–156
 changes brought by, 154–155
 drug therapy management and, 90–91
 evolution of, 148–150
 expectations for future of, 152–153
 guidelines on pharmaceutical services, 9–10
 guidelines on quality assurance issues, 41
 MedWatch program and, 94
 member of FIP, 187
 name change by, 154
 objective of, 156
 organizational issues of, 157
 pharmacy organization merger issues and, 159–162
 pharmacy technicians, 13–14
 Pharm.D degree debate and, 107–110
 plans for future of, 156–157
 principles of, 150–151
 role in clinical movement, 123–124
 role in health-care reforms, 86, 88
Apple, William S., 167, 174–176

B

- Board certification, 110
Board of Pharmaceutical Specialties, 49, 112

C

- California pharmacist-prescribing project, 92
Career management issues
 for pharmacists, 104–141
 lessons for success and, 138–139
Chain drugstores, 1, 5, 108
 pharmacy practice and, 165
 role in educational requirements, 112
Clinical pharmacy
 career options in, 115–116
 clinicians as subculture of pharmacy, 4
 demographic factors in, 117–118
 developing career ladders in, 119–120
 hospital pharmacy and, 123
 integration of, 121–122
 media's attention toward, 124
 medical profession's support for, 124–126
 patient counseling and, 126–128
 pharmaceutical care and, 129–131
 problems associated with, 121
 role in pharmacy's transformation, 26–27
Clozapine (Clozaril), 72
Coalition for Consumer Access to Pharmaceutical Care, 88, 89
Community pharmacies, 1, 2, 63
 Merck-Medco merger and, 64–65
 pharmaceutical prices and, 66–67

- pharmacists' education requirements and, 108
Corporate control
 in health care delivery, 20–21
 of pharmacies, 5–6
Cost containment issues
 health care delivery and, 18–19
 hospital executives and, 45–46
 hospital pharmacy and, 43–44
 managed-care plans and, 47–48
 price controls, pharmaceuticals, 67

D

- Deaths
 caused by contaminated sterile products, 40
 caused by medication errors, 36–38
Developing countries, pharmacists in, 188–189
Directions for Clinical Practice in Pharmacy (conference), 7
Disease-state management, 63
Drug abuse
 pharmacists' role in preventing, 193
 rational policies toward, 190–191
Drug companies. *See* Pharmaceutical industry
Drug distribution systems
 pharmaceutical industry and, 72–73
 pharmacists' role in, 111–112
 reasons for safeguarding, 76
Drug product selection, 52, 54
Drug therapy management
 clinical movement and, 123
 formulary system and, 47–49
 optimal use of, 45
 pharmacists' role in, 57–58, 74–75, 90–91, 130–131
 therapeutic interchange and, 54
Drug-use control
 by pharmacists, 38–39
 cost containment issues and, 43–44
 defined, 44
 drug abuse and, 190–191
Durham–Humphrey Amendment, 172

E

- Educational requirements
 chain stores and, 112
 debate about entry-level, 107–109, 109–111, 162
 Task Force on Pharmacy Education report on, 113–114

F

- Facilities planning of hospital pharmacy, 30–31
Food and Drug Administration, 36, 54, 72
 MedWatch program and, 94
 postmarketing restrictions on drugs and, 95–96
 role in pharmaceuticals promotion, 78
Food, Drug, and Cosmetic Act, 172
Formulary system
 drug therapy and, 47–49
 elements of, 51–52
 pharmaceutical prices and, 69
 pharmacoeconomic issues and, 62
 therapeutic interchange and, 54–57
Franco, Donald E., 151, 172–174, 176–177, 187

G

- Gans, John A., 162–164
Generic substitution, 52, 54, 55
Geriatric population, medication errors and, 37
Group purchasing, 59–61, 63

H

- Harrison Narcotic Act, 191
Health care delivery
 dissatisfaction with, 20–21
 nuclear war issues and, 144–145
 pharmaceutical care and, 135
 transformations in, 18–19

understanding trends in, 138

Health-care reforms

- Congressional speech on, 84–85
- goals for, 80–82
- pharmaceutical prices and, 66–67
- pharmacists' role in, 82–84
- pharmacists and, 88–89
- reasons for failure of, 86–87

Homelessness, mental health problems and, 192

Hospital pharmacy. *See also* Clinical pharmacy

- ambulatory care by, 154
- career options in, 139
- clinical services integration in, 121–122
- cost containment issues and, 43–44, 49
- drug product preparation by, 35
- drug-use control by, 38–39
- elevating status of, 45–46
- facilities planning of, 30–31
- hallmarks of, 6
- leadership priorities for, 18–20
- managed-care plans and, 181
- managers' status in, 28
- Merck-Medco merger and, 64–65
- postgraduate training and, 11–13
- priorities for, 122–124
- process for change in, 141
- technicians in, 170

Hospitals

- group purchasing by, 59–61, 63
- marketing pharmaceuticals to, 58, 62–63
- pharmaceutical services in, 166
- preventing drug-induced illness in, 32–34
- resale of pharmaceuticals by, 76
- role in improving pharmacists' image, 97–98

Humphrey, Hubert H., 171–172

I

Information technology, prescription dispensing and, 21

Integrated health-care systems. *See* Managed-care plans

International Pharmaceutical Abstracts, 173

International Pharmaceutical Federation, 173, 186

Inventory, virtual, 63

J

Joint Commission of Pharmacy Practitioners, 73, 131, 132, 150, 151, 160, 183

L

Large volume parenteral therapy, 40

Leadership issues

- ASHP and, 151
- facilities planning issues and, 30–31
- for hospital pharmacies, 18–20
- for pharmacy departments, 26–27, 45–46
- for pharmacy practice, 22–23

M

Mail-order pharmacies, 1

Managed-care plans

- ambulatory care for enrollees of, 9
- ASHP and, 155
- challenges faced by pharmacies in, 22
- corporate control and, 5
- formulary system in, 47–48
- hospital pharmacy and, 181
- marketing pharmaceuticals to, 58, 62–63, 71
- pharmacy success factors for, 19
- therapeutic interchange issues and, 54–56

Managers

- characteristics of successful, 29
- clinical pharmacists and, 119–120
- opportunities for contributions by, 48–49
- role in preventing medication errors, 35
- role in transforming pharmacies, 46
- status in hospital pharmacy, 28

Marketing by pharmaceutical industry, 58, 62–63

Medication errors. *See also* Adverse drug events (ADEs)

- deaths caused by, 36–37
- drug-use control and, 38–39

- pharmaceutical care and, 135–137
- prevention of, 34–35, 138–139
- quality assurance issues and, 35–36
- reforms to avoid, 37–38
- trouble-shooter, 39

Mental health problems, 192

Merck-Medco merger, 1, 64–65

Millis Commission, The, 33

N

National Association of Chain Drug Stores, 163, 164, 165

National Association of Retail Druggists, 167

National Conference of Catholic Bishops, 144

National Consumers League, 88

National Pharmaceutical Association, 88

Nuclear war issues, 143–145

O

Oddis, Joseph, 176, 186, 187

Operation Desert Storm, 184

P

Patient(s)

- ambulatory, 9–10
- communication between pharmacists and, 6, 101–102
- counseling, 126–128
- death by contaminated sterile products, 40
- death by medication errors, 36–38
- education about medications, 21, 129–131
- pediatric, medication errors, 36–37
- pharmaceutical care and, 133–135
- risk for complications, identifying, 33
- safety issues, 19

Persian Gulf War, 184–186

Pharmaceutical care

- ASHP's future and, 153–155
- clinical, 123, 129–131
- defined, 129–131
- drug misadventure problems and, 135–137
- for ambulatory patients, 9–10
- fundamentals of, 133–134
- goal of, 63
- in hospitals vs. chain drugstores, 166
- managed-care pharmacy and, 48
- pharmacists' contract with America and, 25
- pharmacy practice mission and, 131–133
- public health programs and, 94–95
- ways to encourage, 134
- working on advancing, 19–20

Pharmaceutical industry

- buyouts and mergers in, 182
- drug distribution systems and, 72–73
- drug-therapy monitoring and, 74–75
- marketing by, 58, 62–63
- Merck-Medco merger and, 64–65
- pharmaceutical prices and, 66–70
- pharmaceuticals' promotion by, 71, 77–79
- recruitment by, 140
- therapeutic interchange and, 55–57

Pharmaceutical prices

- criticism about, 68
- drug distribution system and, 72–74
- ethical issues related to, 76–79
- factors deciding, 68–69
- health care reforms and, 66–67
- Merck-Medco merger and, 64–65

Pharmaceuticals

- group purchasing of, 59–61, 63
- marketing of, 62–63
- Medicaid program for, 105
- postmarketing restrictions on, 95–96
- promotion of, 70–71, 77–79
- resale of, 76

Pharmacists. *See also* Educational requirements

- ambulatory-care, 9–10
- autonomy, 145–147
- career management issues for, 140–141
- chain drugstores' behavior toward, 165
- communication between patients and, 6, 101–102

- developing countries, 188–189
 - dispenser as pharmacy subculture, 4
 - dispenser–communicator as pharmacy subculture, 4
 - drug-use control by, 38–39, 44
 - entrepreneur as pharmacy subculture, 4
 - erasing stereotype image of, 102–104
 - expectations for, 119–120
 - health-care reforms and, 81, 88–89
 - job dissatisfaction among, 28
 - leadership issues, 22–23
 - lessons for success for, 138–139
 - manager–administrator as pharmacy subculture, 4
 - manager–leader as pharmacy subculture, 4
 - mission, gaining support for, 99–100
 - patient counseling reassessment by, 126–128
 - Pharm.D degree debate and, 107–109, 112, 113
 - postgraduate training for, 11–13
 - postmarketing restrictions on drugs and, 95–96
 - practitioners vs. providers, 1–3, 159
 - role as prescriber, 92–93
 - role in drug therapy management, 57–58, 74–75, 90–91
 - role in influencing prescriber behavior, 57–59
 - role in medication-system reforms, 37–38
 - role in Persian Gulf War, 184–186
 - role in pharmaceutical promotion, 70–71
 - role in preventing drug abuse, 193
 - role in preventing drug-induced illness, 32–36
 - role in resale of pharmaceuticals, 76
 - shortage of, 182
 - teaching patients, 21
 - therapeutic interchange and, 53–55
 - time management issues for, 141–143
 - ways to improve image of, 97–98
 - Pharmacy benefit managers (PBMs), 56, 57
 - Pharmacy departments
 - challenges faced by, 22
 - clinical services approaches used by, 116
 - elevating status of, 45–46
 - facilities planning, 30–31
 - leadership issues related to, 26–27
 - role in improving pharmacists' image, 101–102
 - role in preventing drug-induced illness, 33–34
 - Pharmacy organization(s)
 - chain drugstores and, 165–166
 - consolidation of, 159–161
 - foundation organization, relevance, 167–168
 - role in elevating pharmacy profession, 162–164
 - technicians in, 169–170
 - unity, 161–162
 - Pharmacy practice
 - ASHP's role in elevating, 151–152
 - chain drugstores and, 165
 - mission statement of, 132–133
 - needs of, 149
 - Pharmacy profession, 2
 - achieving full potential of, 7–8
 - APhA's role in elevating, 162–164
 - clinical movement of, 26–27
 - corporate control of, 5–6
 - cultures and subcultures of, 3–4
 - demographics and clinical careers in, 117–118
 - developing career ladders in, 119–120
 - goal of, 7, 136, 147
 - health-system practice, 148–150
 - history, 178–180
 - in developing countries, 188–189
 - inaccurate perceptions about, 104–106
 - integrating clinical pharmacy into, 115–116
 - mail order, 1
 - major happenings in 1980s in, 180–184
 - managed-care, 47–48
 - managing workers in, 28
 - Merck-Medco merger and, 64–65
 - mission of, 131–133, 183
 - opportunities for advancement, 48–49
 - outpatient, 10
 - paradigm shift in, 21
 - professional imperative, 22–23
 - role in handling public health issues, 103–104
 - role in health-care reforms, 82–84
 - role in society, 111–112
 - technical personnel status in, 13–15
 - technicians' role in, 169–170
 - transforming, 46
 - Pharmacy providers, 1–3, 159
 - Pharmacy technicians
 - in pharmacy organizations, 169–170
 - issues related to, 15–17
 - need and training for, 123
 - role of, 169
 - status, 13–15
 - Pharm.D degree
 - debate about, 107–109, 112
 - entry-level vs. advanced degree, 110, 113, 162
 - types of, 109
 - Physicians
 - drug misadventure problems and, 136
 - pharmacists' role in influencing, 57–59
 - support for clinical pharmacy, 124–126
 - Prescription Drug Marketing Act, 76
 - Provost, George P., 176–177
 - Public health issues/programs
 - pharmaceutical care and, 94–95
 - pharmacists' role in handling, 103–104
 - Public policy
 - ASHP and, 151
 - drug therapy management and, 90–91
 - health-care reforms and, 80–82, 84–87
 - pharmacists as prescriber and, 92–93
 - pharmacy's role in, 82–84, 88–89
 - postmarketing restrictions on drugs and, 95–96
 - public health programs and, 94–95
-
- Q**
-
- Quality assurance issues
 - medication errors and, 35–36
 - sterile products and, 40–41
-
- R**
-
- Residency training
 - ASHP's role in addressing, 151
 - challenges and opportunities, 12–13
 - for pharmacists, 11–13
 - Robinson-Patman Act, 76
-
- S**
-
- Safety issues
 - drug-induced illness and, 32–34
 - drug-use control and, 44
 - hospital cutbacks and, 19
 - medication errors and, 34–36
 - sterile products and, 40–41
 - Schlegel, John F., 167
 - Specialty certification, 110
 - Standards of practice, 6
 - Sterile products, 40–41
 - Subcultures of pharmacy, 3–4
-
- T**
-
- Task Force on Pharmacy Education, 113, 114
 - Therapeutic interchange
 - rise of, 55–57
 - understanding, 53–55
 - Third World, pharmacists in, 188–189
 - Time management issues, 141–143
-
- W**
-
- World Health Organization (WHO), 188, 189
-
- Z**
-
- Ziegler, Ronald, 164–166